453
Views
16
CrossRef citations to date
0
Altmetric
Review Article

AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy

&
Pages 186-194 | Received 12 Jan 2016, Accepted 20 Jun 2016, Published online: 15 Jul 2016
 

Abstract

Amphotericin B (AMPH-B) is a polyene antifungal agent with a superior and broad fungicidal spectrum, but its administration at a dose sufficient for treatment is difficult because of dose- and duration-dependent nephrotoxicity. To solve this dilemma, a liposomal formation of AMPH-B that achieved reduction of adverse effects while maintaining the efficacy, AmBisome® (L-AMB), was developed. In L-AMB, AMPH-B molecules are stabilized by phospholipids and cholesterol in the liposomal lipid bilayer, reducing the cytotoxicity for animal cells compared with that of the free-form AMPH-B. In addition, extravascular permeation of L-AMB is limited in normal tissue because of the liposome particle size (particle diameter: 100 nm or smaller), a high blood level is maintained and the distribution in organs, including the kidney is reduced, contributing to the improvement of the safety. On the other hand, vascular permeation increases due to inflammation and damage by fungal invasion, which increases L-AMB transfer from the circulation to lesions and its antifungal activity. Furthermore, since the parameter most closely correlated with the in vivo outcome of L-AMB is Cmax/MIC, the pharmacokinetic (PK) characteristics of L-AMB, which result in a high blood level than that for the free-form AMPH-B, is advantageous for antifungal activity. Incorporation of AMPH-B into the liposomal membrane resulted in PK characteristics of L-AMB markedly different from those of AMPH-B, and the superior efficacy and safety were achieved based on these characteristics. In this review, the relationship between the PK characteristics of L-AMB and safety/efficacy is introduced.

Declaration of interest

No financial support was received from third parties. The authors are employees of Sumitomo Dainippon Pharma Co., Ltd., but hold no stock options in the company. We have not accepted reimbursement for preparing this article. The authors alone are responsible for the content and writing of this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.